Beijing Bohui Innovation Biotechnology Co., Ltd. (SZSE:300318) signed a share issuance agreement to acquire 100% stake in Adchim SAS from Zhuhai Aosen Investment Co., Ltd. for approximately CNY 660 million on February 17, 2020. Beijing Bohui Innovation Biotechnology Co., Ltd. signed a Issuance of Shares Agreement Supplement Agreement to acquire 100% stake in Adchim SAS from Zhuhai Aosen Investment Co., Ltd. on November 6, 2020. Beijing Bohui Innovation is issuing 110.8 million of its shares. After the transaction, Zhuhai Aosen Investment Co., Ltd. will hold 20.65% of Beijing Bohui Innovation Biotechnology Co., Ltd. shares. Beijing Bohui Innovation Biotechnology Co., Ltd.'s non-public issuance of shares to raise supporting funds does not exceed CNY 420 million. For the year ended December 31, 2019, Adchim SAS reported total assets of CNY 551.1 million, total common equity of CNY 439.8 million, total revenues of CNY 277 million and net profit of CNY 23.7 million. The transaction is subject to the consummation of due diligence and the approval of the Beijing Bohui's Directors approval, Beijing Bohui's shareholder approval, Inner Mongolia Junzheng Energy & Chemical Group Co., Ltd.'s internal approval. The approval of Chine Securities Regulatory Approval (CSRC) and other necessary approvals. The shares Zhuhai Aosen Investment Co., Ltd. subscribes to, cannot be transferred within 18 months from the issuance closing date. As of February 17, 2020, Inner Mongolia Junzheng, the parent of Zhuhai Aosen Investment Co., Ltd., approved the transaction. Beijing Bohui's Director's approved the transaction. Zhuhai Aosen Investment Co., Ltd. will use the proceeds for the payment of CNY 77.5 million for the Chromatographic column production line automation upgrade project, CNY 45 million for R&D center construction project, CNY 77.5 million for Marketing center construction and information system upgrade project, CNY 20 million for Supplement working capital and CNY 20 million for transaction’s relevant fees. Aodu Jiya, A Lima of Moore Stephens Da Hua acted as accountant, Liu Siliang and Xue Yuting of Grandway Law Offices acted as legal advisor, EC Mergers & Acquisitions and DONGXING SECURITIES Company Limited (SHSE:601198) acted as financial advisors to Beijing Bohui Innovation Biotechnology Co., Ltd. Beijing Bohui Innovation Biotechnology Co., Ltd. (SZSE:300318) cancelled the acquisition of 100% stake in Adchim SAS from Zhuhai Aosen Investment Co., Ltd. on September 6, 2021. Beijing Bohui's thirteenth meeting of the seventh board of directors and the ninth meeting of the seventh board of supervisors on September 6, 2021, and reviewed and approved the termination of the transaction.